Evidence check: FTO in the context of Wechseljahre

The question about FTO (fat mass and obesity-associated gene) in the context of menopause is relevant because FTO variants (e.g., rs9939609) are among the most robustly replicated genetic risk factors for higher BMI and obesity. During menopause, hormonal shifts often lead to metabolic changes that promote weight gain. GWAS evidence clearly links FTO risk alleles with increased BMI, also in menopausal women. However, the effect size is modest (about 0.3 kg per risk allele) and strongly modulated by lifestyle factors such as diet and physical activity. No randomized controlled trials have specifically shown that FTO-based personalized advice outperforms general lifestyle recommendations in menopause. Therefore, clinical utility is limited: an FTO risk genotype increases susceptibility but is not deterministic. Practical focus should remain on proven strategies like adequate protein intake, resistance training, and stress management. A DNA test alone does not justify a change in clinical management.